Diabetes has been linked to increased prevalence of dementia, but the link between diabetic retinopathy (DR) and Alzheimer's disease (AD) remains unclear.
Objective
This study aimed to evaluate potential associations between DR and AD-related protein biomarkers in plasma and ocular fluid.
Methods
A prospective, cross-sectional study collected human blood, vitreous, aqueous, and tear samples and measured amyloid-β (Aβ40, Aβ42), total-tau (t-tau), phosphorylated-tau (ptau181), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) by digital immunoassays.
Results
The study included 79 eyes (79 patients) [41 females (59.4%); mean (SD) age 57.1 (12.2) years] of which DR was present in 44 (55.7%). All six biomarkers were significantly higher in plasma in participants with DR compared to those without DR [Aβ40 p = 0.002, Aβ42 p = 0.002, t-tau = 0.013, ptau181 p = 0.005, GFAP p = 0.010, and NfL p < 0.001]. Within vitreous, DR participants had significantly elevated t-tau (p = 0.002), ptau181 (p = 0.049), and NfL (p = 0.006); and within aqueous, higher NfL (p = < 0.001). Neuropsychological testing scores were lower in participants with DR than those without but did not reach statistical significance (Montreal-Cognitive-Assessment: p = 0.070; Mini-Mental-State-Exam: p = 0.057).
Conclusions
This study showed significant increases of AD associated protein biomarkers in plasma, vitreous, and aqueous in patients with DR. These results support a potential biological link between DR and AD pathology and suggest that DR, which tends to occur in younger individuals, may be a predictive factor for AD.
PrinceMWimoAGuerchetM, et al.World Alzheimer Report 2015. The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends. London: Alzheimer's Disease International, 2015.
CiudinAEspinosaASimó-ServatO, et al.Type 2 diabetes is an independent risk factor for dementia conversion in patients with mild cognitive impairment. J Diabetes Complications2017; 31: 1272–1274.
5.
de Almeida FariaACRDall'AgnolJFGouveiaAM, et al.Risk factors for cognitive decline in type 2 diabetes mellitus patients in Brazil: a prospective observational study. Diabetol Metab Syndr2022; 14: 105.
6.
JashKGondaliyaPKiraveP, et al.Cognitive dysfunction: a growing link between diabetes and Alzheimer's disease. Drug Dev Res2020; 81: 144–164.
7.
LacyMEGilsanzPKarterAJ, et al.Long-term glycemic control and dementia risk in type 1 diabetes. Diabetes Care2018; 41: 2339–2345.
8.
XiaSSXiaWLHuangJJ, et al.The factors contributing to cognitive dysfunction in type 2 diabetic patients. Ann Transl Med2020; 8: 104.
9.
ChengGHuangCDengH, et al.Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J2012; 42: 484–491.
10.
GudalaKBansalDSchifanoF, et al.Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig2013; 4: 640–650.
11.
NguyenTTTaQTHNguyenTKO, et al.Type 3 diabetes and its role implications in Alzheimer's disease. Int J Mol Sci2020; 21: 3165.
12.
NguyenTTTaQTHNguyenTTD, et al.Role of insulin resistance in the Alzheimer's disease progression. Neurochem Res2020; 45: 1481–1491.
13.
AbnerELNelsonPTKryscioRJ, et al.Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology. Alzheimers Dement2016; 12: 882–889.
14.
AhtiluotoSPolvikoskiTPeltonenM, et al.Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology2010; 75: 1195–1202.
15.
EtieneDKraftJGanjuN, et al.Cerebrovascular pathology contributes to the heterogeneity of Alzheimer's disease. J Alzheimers Dis1998; 1: 119–134.
16.
MannDM. The neuropathology of Alzheimer's disease: a review with pathogenetic, aetiological and therapeutic considerations. Mech Ageing Dev1985; 31: 213–255.
17.
OttBRJonesRNDaielloLA, et al.Blood-cerebrospinal fluid barrier gradients in mild cognitive impairment and Alzheimer's disease: relationship to inflammatory cytokines and chemokines. Front Aging Neurosci2018; 10: 245.
18.
de LeonMJGeorgeAEFerrisSH, et al.Regional correlation of PET and CT in senile dementia of the Alzheimer type. AJNR Am J Neuroradiol1983; 4: 553–556.
19.
FaulstichME. Brain imaging in dementia of the Alzheimer type. Int J Neurosci1991; 57: 39–49.
20.
WaldronAMWintmoldersCBottelbergsA, et al.In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-β load in aged APPPS1-21 mice. Alzheimers Res Ther2015; 7: 76.
21.
WurtmanR. Biomarkers in the diagnosis and management of Alzheimer's disease. Metabolism2015; 64: S47–S50.
22.
JackCRJrBennettDABlennowK, et al.NIA-AA Research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement2018; 14: 535–562.
23.
TeunissenCEVerberkIMWThijssenEH, et al.Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol2022; 21: 66–77.
24.
LeeCSLarsonEBGibbonsLE, et al.Associations between recent and established ophthalmic conditions and risk of Alzheimer's disease. Alzheimers Dement2019; 15: 34–41.
25.
LeeCSKrakauerCSuYR, et al.Diabetic retinopathy and dementia association, beyond diabetes severity. Am J Ophthalmol2023; 249: 90–98.
26.
ChanRNFTangZChanVTT, et al.The cross-sectional and longitudinal relationship of diabetic retinopathy to cognitive impairment: a systematic review and meta-analysis. Eye (Lond)2023; 37: 220–227.
27.
WrightLMSteinTDJunG, et al.Association of cognitive function with amyloid-β and tau proteins in the vitreous humor. J Alzheimers Dis2019; 68: 1429–1438.
28.
SubramanianMLVigVChungJ, et al.Neurofilament light chain in the vitreous humor of the eye. Alzheimers Res Ther2020; 12: 111.
29.
VigVGargITuz-ZahraF, et al.Vitreous humor biomarkers reflect pathological changes in the brain for Alzheimer's disease and chronic traumatic encephalopathy. J Alzheimers Dis2023; 93: 1181–1193.
30.
FereshetianSAgranatJSSiegelN, et al.Protein and imaging biomarkers in the eye for early detection of Alzheimer's disease. J Alzheimers Dis Rep2021; 5: 375–387.
31.
HussainASheikhZSubramanianM. The eye as a diagnostic tool for Alzheimer's disease. Life (Basel)2023; 13: 726.
32.
SampaniKNessSTuz-ZahraF, et al.Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study. Alzheimers Res Ther2024; 16: 192.
33.
JackCRJrBennettDABlennowK, et al.A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology2016; 87: 539–547.
34.
HanssonOEdelmayerRMBoxerAL, et al.The Alzheimer's association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement2022; 18: 2669–2686.
35.
Montoliu-GayaLAloscoMLYhangE, et al.Optimal blood tau species for the detection of Alzheimer's disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study. Acta Neuropathol2023; 147: 5.
36.
PedersenFNStokholmLPouwerF, et al.Diabetic retinopathy predicts risk of Alzheimer's disease: a Danish registry-based nationwide cohort study. J Alzheimers Dis2022; 86: 451–460.
37.
OuyangFYuanPJuY, et al.Alzheimer's disease as a causal risk factor for diabetic retinopathy: a Mendelian randomization study. Front Endocrinol (Lausanne)2024; 15: 1340608.
38.
BarberAJ. Diabetic retinopathy: recent advances towards understanding neurodegeneration and vision loss. Sci China Life Sci2015; 58: 541–549.
39.
SimóRStittAWGardnerTW. Neurodegeneration in diabetic retinopathy: does it really matter?Diabetologia2018; 61: 1902–1912.
40.
FragiottaSPinazo-DuránMDScuderiG. Understanding neurodegeneration from a clinical and therapeutic perspective in early diabetic retinopathy. Nutrients2022; 14: 792.
41.
MizutaniMKernTSLorenziM. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest1996; 97: 2883–2890.
42.
BarberAJLiethEKhinSA, et al.Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest1998; 102: 783–791.
43.
NingXBaoyuQYuzhenL, et al.Neuro-optic cell apoptosis and microangiopathy in KKAY mouse retina. Int J Mol Med2004; 13: 87–92.
44.
BarberAJAntonettiDAKernTS, et al.The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci2005; 46: 2210–2218.
45.
Lopes de FariaJMRussHCostaVP. Retinal nerve fibre layer loss in patients with type 1 diabetes mellitus without retinopathy. Br J Ophthalmol2002; 86: 725–728.
46.
OzdekSLonnevilleYHOnolM, et al.Assessment of nerve fiber layer in diabetic patients with scanning laser polarimetry. Eye (Lond)2002; 16: 761–765.
47.
TakahashiHGotoTShojiT, et al.Diabetes-associated retinal nerve fiber damage evaluated with scanning laser polarimetry. Am J Ophthalmol2006; 142: 88–94.
48.
AsefzadehBFischBMParenteauCE, et al.Macular thickness and systemic markers for diabetes in individuals with no or mild diabetic retinopathy. Clin Exp Ophthalmol2008; 36: 455–463.
49.
BiallosterskiCvan VelthovenMEMichelsRP, et al.Decreased optical coherence tomography-measured pericentral retinal thickness in patients with diabetes mellitus type 1 with minimal diabetic retinopathy. Br J Ophthalmol2007; 91: 1135–1138.
50.
Bronson-CastainKWBearseMAJrNeuvilleJ, et al.Adolescents with type 2 diabetes: early indications of focal retinal neuropathy, retinal thinning, and venular dilation. Retina2009; 29: 618–626.
51.
BrowningDJFraserCMClarkS. The relationship of macular thickness to clinically graded diabetic retinopathy severity in eyes without clinically detected diabetic macular edema. Ophthalmology2008; 115: 533–539.e532.
52.
NilssonMvon WendtGWangerP, et al.Early detection of macular changes in patients with diabetes using Rarebit Fovea Test and optical coherence tomography. Br J Ophthalmol2007; 91: 1596–1598.
53.
OshitariTHanawaKAdachi-UsamiE. Changes of macular and RNFL thicknesses measured by Stratus OCT in patients with early stage diabetes. Eye (Lond)2009; 23: 884–889.
54.
van DijkHWKokPHGarvinM, et al.Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci2009; 50: 3404–3409.
55.
El-FayoumiDBadr EldineNMEsmaelAF, et al.Retinal nerve fiber layer and ganglion cell complex thicknesses are reduced in children with type 1 diabetes with no evidence of vascular retinopathy. Invest Ophthalmol Vis Sci2016; 57: 5355–5360.
56.
YuQXiaoYLinQ, et al.Two-year longitudinal study on changes in thickness of the retinal nerve fiber layer and ganglion cell layer in children with type 1 diabetes mellitus without visual impairment or diabetic retinopathy. Curr Eye Res2022; 47: 1218–1225.
57.
LeeMWLeeWHRyuCK, et al.Peripapillary retinal nerve fiber layer and microvasculature in prolonged type 2 diabetes patients without clinical diabetic retinopathy. Invest Ophthalmol Vis Sci2021; 62: 9.
58.
GundoganFCAkayFUzunS, et al.Early neurodegeneration of the inner retinal layers in type 1 diabetes mellitus. Ophthalmologica2016; 235: 125–132.
59.
KartiONalbantogluOAbaliS, et al.Retinal ganglion cell loss in children with type 1 diabetes mellitus without diabetic retinopathy. Ophthalmic Surg Lasers Imaging Retina2017; 48: 473–477.
60.
Mohd-IlhamITaiELMSuhaimiH, et al.Evaluation of macular and retinal nerve fiber layer thickness in children with type 1 diabetes mellitus without retinopathy. Korean J Ophthalmol2021; 35: 287–294.
61.
HuangJLiYChenY, et al.Multifocal electroretinogram can detect the abnormal retinal change in early stage of type2 DM patients without apparent diabetic retinopathy. J Diabetes Res2021; 2021: 6644691.
62.
JiaYLinQXiaoY, et al.Are we overlooking the neurodegeneration in the early stage of type 1 diabetes mellitus without visual impairment or diabetic retinopathy: is it probably occurred before retinal vasculature dysfunction?Curr Eye Res2023; 48: 433–440.
63.
FortuneBSchneckMEAdamsAJ. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci1999; 40: 2638–2651.
64.
ZengYCaoDYuH, et al.Early retinal neurovascular impairment in patients with diabetes without clinically detectable retinopathy. Br J Ophthalmol2019; 103: 1747–1752.
65.
BearseMAJrAdamsAJHanY, et al.A multifocal electroretinogram model predicting the development of diabetic retinopathy. Prog Retin Eye Res2006; 25: 425–448.
66.
HanYBearseMAJrSchneckME, et al.Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy. Invest Ophthalmol Vis Sci2004; 45: 948–954.
67.
HarrisonWWBearseMAJrSchneckME, et al.Prediction, by retinal location, of the onset of diabetic edema in patients with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci2011; 52: 6825–6831.
68.
NgJSBearseMAJrSchneckME, et al.Local diabetic retinopathy prediction by multifocal ERG delays over 3 years. Invest Ophthalmol Vis Sci2008; 49: 1622–1628.
69.
AntonettiDASilvaPSStittAW. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat Rev Endocrinol2021; 17: 195–206.
70.
GarhöferGChuaJTanB, et al.Retinal neurovascular coupling in diabetes. J Clin Med2020; 9: 2829.
71.
StarrJMWardlawJFergusonK, et al.Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry2003; 74: 70–76.
72.
van SlotenTTSedaghatSCarnethonMR, et al.Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. Lancet Diabetes Endocrinol2020; 8: 325–336.
73.
WoerdemanJvan DuinkerkenEWattjesMP, et al.Proliferative retinopathy in type 1 diabetes is associated with cerebral microbleeds, which is part of generalized microangiopathy. Diabetes Care2014; 37: 1165–1168.
74.
SanahujaJAlonsoNDiezJ, et al.Increased burden of cerebral small vessel disease in patients with type 2 diabetes and retinopathy. Diabetes Care2016; 39: 1614–1620.
75.
LittleKLlorián-SalvadorMScullionS, et al.Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline. Trends Endocrinol Metab2022; 33: 50–71.
76.
EbrahimiMThompsonPLauerAK, et al.The retina-brain axis and diabetic retinopathy. Eur J Ophthalmol2023; 33: 2079–2095.
77.
KaštelanSNikuševa-MartićTPašalićD, et al.Genetic and epigenetic biomarkers linking Alzheimer's disease and age-related macular degeneration. Int J Mol Sci2024; 25: 7271.
78.
ButovskyORosenzweigN. Alzheimer's disease and age-related macular degeneration: shared and distinct immune mechanisms. Immunity2025; 58: 1120–1139.
79.
SenSSaxenaRTripathiM, et al.Neurodegeneration in Alzheimer's disease and glaucoma: overlaps and missing links. Eye (Lond)2020; 34: 1546–1553.
80.
HoKBodiNESharmaTP. Normal-tension glaucoma and potential clinical links to Alzheimer's disease. J Clin Med2024; 13: 1948.
81.
ThijssenEHLa JoieRStromA, et al.Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol2021; 20: 739–752.
